Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.54 |
| ▸ | PYGL | P06737 | 1/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CCKAR | P32238 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | UBASH3B | Q8TF42 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12658563 | 0.88 | ALDH1A1 (0.59) | ACEPYGL | |
| SCHEMBL1827012 | 0.84 | CA2 (0.51) | CA2CA1PIN1L3MBTL1UBASH3B | |
| SCHEMBL2998841 | 0.79 | F11 (0.65) | PTPN1CA2ACECA1GPR132 | |
| SCHEMBL2998848 | 0.79 | F11 (0.65) | PTPN1CA2ACECA1GPR132 | |
| SCHEMBL111235 | 0.78 | ACE (0.76) | PTPN1CA2ACECA1GPR132 | |
| SCHEMBL528464 | 0.78 | ACE (0.76) | PTPN1CA2ACECA1GPR132 | |
| SCHEMBL111236 | 0.78 | ACE (0.76) | PTPN1CA2ACECA1GPR132 | |
| SCHEMBL6786437 | 0.77 | AGTR2 (0.56) | PTPN1CA2ACECA1GPR132 | |
| SCHEMBL6790346 | 0.77 | AGTR2 (0.56) | PTPN1CA2ACECA1GPR132 | |
| SCHEMBL6786433 | 0.77 | AGTR2 (0.56) | PTPN1CA2ACECA1GPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | claimed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | claimed |
| US-20060154977-A1 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD, CORPORATION | 2006-07-13 | — | — | US | claimed |
| EP-1511736-A4 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2006-06-07 | — | — | EP | claimed |
| EP-1511736-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | Cortical Pty Ltd (AU) | 2005-03-09 | — | — | EP | claimed |
| WO-2003104203-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2003-12-18 | — | — | WO | claimed |
| EP-2319838-A1 | Therapeutic Molecules and Methods-1 | Cortical Pty Ltd (AU) | 2011-05-11 | — | — | EP | disclosed |
| EP-2319838-A1 | Therapeutic Molecules and Methods-1 | Cortical Pty Ltd (AU) | 2011-05-11 | — | — | EP | disclosed |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | disclosed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | disclosed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | disclosed |
| US-20060154977-A1 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD, CORPORATION | 2006-07-13 | — | — | US | disclosed |
| EP-1511736-A4 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2006-06-07 | — | — | EP | disclosed |
| EP-1511736-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | Cortical Pty Ltd (AU) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003104203-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154977-A1 | Therapeutic molecules and methods-1 | MIF, IL1B, IL1A | PTPN1 2239/4885CA2 2519/4885ACE 796/4885 |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MIF, IL1B, IL1A | PTPN1 2239/4885CA2 2519/4885ACE 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.